Hironaga Satake

Nankoku, 7838505, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

Correction: Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.

Correction: Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.

Journal: Scientific reports

Published: August 31, 2026

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Journal: JCO precision oncology

Published: July 01, 2026

Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis.

Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: June 01, 2026

Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis.

Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: May 09, 2026

Facility-level JSMO specialist availability and reconstructable treatment-process measures in colorectal cancer using C-CAT data.

Facility-level JSMO specialist availability and reconstructable treatment-process measures in colorectal cancer using C-CAT data.

Journal: International journal of clinical oncology

Published: May 08, 2026

High therapeutic efficacy of triplet therapy in unresectable or metastatic colorectal cancer and its optimal application strategies.

High therapeutic efficacy of triplet therapy in unresectable or metastatic colorectal cancer and its optimal application strategies.

Journal: International journal of clinical oncology

Published: April 17, 2026

Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer.

Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer.

Journal: iScience

Published: March 15, 2026

Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701.

Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: December 12, 2025

Bridging the distance in precision oncology: a nationwide survey on institutional perspectives toward telemedicine and decentralized trials in Japan.

Bridging the distance in precision oncology: a nationwide survey on institutional perspectives toward telemedicine and decentralized trials in Japan.

Journal: International journal of clinical oncology

Published: December 02, 2025

Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.

Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.

Journal: Scientific reports

Published: October 27, 2025

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 14, 2025

A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.

A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.

Journal: Japanese journal of clinical oncology

Published: October 11, 2025

Showing 1-12 of 127

Last Updated: 09/26/2026